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Abstract
When patients present to an emergency room (ER) with a nosebleed, one technique that physicians
employ is the application of nasal packing. Merocel is a common nasal pack utilized in ER because
of their low cost. Rapid Rhino is a nasal packing that is more comfortable for patients but is more
costly than Merocel. Costing for epistaxis treatment is more than initial treatment costs and needs
to consider rebleed rates. Using a retrospective cohort study design with covariates adjusted by
propensity scores, we compared the costs associated with Merocel, and Rapid Rhino from the
hospital and provincial healthcare perspectives. Merocel had a 26/62 (42%) total rebleed rate
contrasted to Rapid Rhino’s 4/17 (24%). For both the hospital and provincial perspectives, our
sample did not provide evidence that there was difference in costs between Merocel and Rapid
Rhino.
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Summary for Lay Audience
When epistaxis occurs, the bleed is often self-limited. However, in some cases the
bleeding does not stop, and the patient requires additional medical intervention.
Emergency room physicians will typically attempt further conservative management, like
applying pressure to the nose and decongestion before consideration of invasive methods.
Nasal packing is one option when these conservative methods fail. Merocel is a
commonly utilized nasal pack in the ER as the direct material costs for these packs are
relatively cheaper to other options. In comparison, other nasal packs like Rapid Rhino are
more expensive but more comfortable for patients.
However, costs associated with nasal packing are more than just direct material costs. A
major contributor to costs is rebleeds. If patients experience a greater rate of rebleed
using one pack, they return to the ER again incurring additional costs. Unfortunately,
there are few studies comparing rebleed rates of Merocel to Rapid Rhino directly, and
even fewer cost-analysis that include rebleed rates for both nasal packs.
A retrospective review of medical charts for adult anterior epistaxis patients during the
year 2018 presenting at University and Victoria hospital ERs was conducted. Patients
were followed-up for two weeks to assess rebleed rates. Total costs were assessed using
both inverse probability weight and covariate balancing propensity score weighting for
the hospital and provincial health care perspectives.
The sample size for Rapid Rhino was 17, while the Merocel sample size was 62. Our
total rate of rebleeds in Merocel was 42% (26/62) compared to 24% (4/17) in Rapid
Rhino. Patients receiving Rapid Rhino have statistically non-significant difference in
costs per patient ($61.61, 95% CI: -$127.84 to $251.05) for the hospital perspective as
well as the provincial health care perspective ($78.14, 95% CI: -$89.54 to $245.83). Our
sample did not suggest differences in costs for using Merocel and Rapid Rhino in
treatment of epistaxis in the emergency room.
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Chapter 1
1 Introduction
1.1 Epistaxis
Epistaxis occurs when small vessels within the nasal cavity rupture. Evidence suggests
that approximately 60% of the population experiences epistaxis at least once in their
lifetime.1 There are two types of epistaxis: posterior and anterior. Posterior epistaxis
occurs when bleeding is located at the back of the nasal cavity. This form of epistaxis is
rare, but often more serious and requires immediate medical attention.2 Comparatively,
anterior epistaxis occurs along the nasal septum at the front of the nose. Fortunately,
anterior epistaxis comprises the majority of cases for both children and adults. Nasal
trauma and mucosal dehydration are the most common causes of anterior epistaxis. In
adults, hypertension and anticoagulation can also increase risk of epistaxis.3
In the United States, 6% of the population sees a healthcare professional for epistaxis in
their lifetime; of these, about 90% are anterior epistaxis.1 Application of pressure for 15 20 minutes is recommended prior to seeking medical attention.4 There are exceptions to
this rule: if excessive bleeding or light-headedness occurs, patients are recommended to
seek medical help immediately.4 Although no step-by-step procedure for stopping
anterior epistaxis in the emergency room (ER) exists, there are many permutations and
nuances to effective management. Each case is different and may require a combination
of interventions. Certain interventions are also more comfortable for patients and easier
to perform for physicians. These interventions have different costs and effectiveness
associated with them.
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1.2 Risk Factors
Risk factors such as hypertension and use of anticoagulants are known to be associated
with higher risks of refractory anterior epistaxis. A recent meta-analysis and systematic
review found an association between hypertension and epistaxis. Min et al. reported an
odds ratio of 1.53 [95% CI: 1.18-1.99], indicating a significant increase in the risk of
epistaxis for individuals with hypertension compared to a control group with no
hypertension.5 Similarly, a retrospective review compared the occurrence of epistaxis in
35,749 patients with hypertension to 35,749 patients without hypertension.6 They
concluded that hypertension was associated with an increased risk of epistaxis and more
ER visits.6 It is important to note that the current clinical guidelines highlight an
association rather then a causal link between hypertension and epistaxis.7
Anticoagulants or blood-thinner medications reduce the risk of blood clotting in patients
with atrial fibrillation but may increase the chance of epistaxis. Chaaban et al.8 reviewed
older patient’s charts (>75 years of age) to determine the increase of patient visits to the
ER for patients with a history of pulmonary embolism, atrial fibrillation, or a heart valve
(defined as the “anticoagulant group”). In the “anticoagulant group”, patients who also
had congestive heart failure (CHF) and chronic obstructive pulmonary diseases (COPD)
visited the ER more frequently for epistaxis (p < 0.05) compared to patients without these
comorbidities.8 However, the patients were not confirmed to have utilized anticoagulants
and this increased rate in epistaxis seem to be attributed to CHF and COPD. A
prospective study of 290 ER patients with epistaxis shows an association between
anticoagulation use and epistaxis and demonstrates how patients on anticoagulants make
up a large portion of in-patient ER admission rates.9 In this study, 119 patients required
an otolaryngologist to assess the patient, and 74 (62%) of those patients were on
anticoagulants.9
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Goljo et al. conducted a retrospective cross-sectional study in the United States using a
national hospital inpatient sample assessed occurrence of epistaxis in 16,828 patients.10
These patients had a mean age of 68 with 52% being male. In this study, out of the
16,828 patients that were admitted to a hospital with epistaxis as a diagnosis,
approximately 3,494 (21%) of those patients were on long-term anticoagulants.10
Furthermore, Newton et al.11 conducted a retrospective study for anterior epistaxis in the
ER using patient medical charts. Of the 353 patients, 49% were female and 51% male. In
this study, 56% of these patients had hypertension and 61% were on an anticoagulant.11
The majority of patients in this study ranged from 60-70 years of age.11
The use of certain anticoagulants appears to be associated with a higher risk of
epistaxis.12 For example, a recent retrospective cohort study included 2098 patients that
received apixaban, 474 patients on dabigatran, 3106 patients on rivaroxaban, and 1403
patients receiving warfarin from 2014 to 2019.12 They followed patients to assess risk of
epistaxis and used inverse probability weighting to adjust for confounders. The
confounders they included into this study were age, sex, hypertension, bleeding disorders
and all the variables in the Charlson comorbidity index (except AIDS), prior history of
venous thromboembolic events, prior gastrointestinal bleeding and epistaxis events
requiring hospital admission, treatment indication, region of residence, and concomitant
use of anti-histamines, antihypertensives, antiplatelets, corticosteroids, nonsteroidal antiinflammatory drugs, proton pump inhibitors, selective serotonin receptor inhibitors, and
statins.12 The study concluded that warfarin had higher rates of epistaxis compared to
apixaban, dabigatran and rivaroxaban at the 5% significance level.12
A variety of comorbidities affect epistaxis management and costs. For example, there are
recommendations in the literature for patients to stop smoking in order to lower their
chances of epistaxis recurrence.2 Furthermore, a prospective longitudinal study from
March 2006 to March 2007 noted that out of the 54 patients discharged with nasal
packing, 48% were smokers and 55% of patients with recurrence of epistaxis were also
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smokers.13 Some literature on clinical guidelines in managing epistaxis note that patients
who abuse drugs or have blood clotting disorders tend to experience a higher rate of
epistaxis.1-2 Goljo et al. found that patients with alcohol abuse, sinonasal disease, renal
disease had an increased length of stay in the hospital and higher costs associated with
them.10 Chaaban et al. also found that patients with congestive heart failure, diabetes
mellitus, and obstructive sleep apnea had higher rates of recurrent ER epistaxis visits
compared to patients without these comorbidities.8

1.3 Guidelines in Managing Epistaxis
Although there are general recommendations in the literature for treating epistaxis, there
is no consensus on the exact steps to follow to stop an active nosebleed. The first
recommendation is to apply pressure to the nose which indirectly compresses the anterior
septum. Patients can apply pressure by themselves or use a nasal compression clip. The
amount of time to apply pressure is not consistent between studies, but 10 minutes is
often used based on coagulation physiology and consensus.14,15 However, knowledge of
epistaxis management in healthcare professionals can be relatively poor. One study found
that less than 1/3 of ER physicians, nurses, and residents knew proper first-aid measures
for epistaxis.16 Simple education for patients regarding the appropriate first-aid measures
for epistaxis have been shown to reduce re-visits to the ER by more than 50%.17
If bleeding continues, and an obvious source of active bleeding is visible, then
cauterization is the second step. Topical silver nitrate is the most common type of cautery
for anterior epistaxis, but electrocautery or thermal cautery can also be used. When silver
nitrate encounters water (or blood), a chemical reaction occurs to form nitric acid and
silver oxide. Nitric acid provides a chemical burn to the area of application, while silver
ions obstruct any bleeding vessels.18 After cauterizing the bleed, a gel is recommended to
allow for the nose to heal.19 Medications such as oxymetazoline, topical epinephrine, and
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tranexamic acid can all be used in conjunction or as alternatives to cautery to stop
epistaxis.20-22
If a health practitioner cannot visualise the area of the bleed or the patient is continuing to
bleed after the above-mentioned methods have failed, they may consider packing the
nose with dissolvable or non-dissolvable material.7 It is estimated that around 20% of all
epistaxis patients required nasal packing.23 Two common non-dissolvable nasal packs
include Merocel and Rapid Rhino.24 Other non-dissolvable packs include Vaseline gauze,
Epistat, Rhino Rockets, and Bismuth Iodoform Paraffin Paste (BIPP) gauze. Dissolvable
packing material can also be used but acts more as a hemostatic matrix rather than
applying tamponading pressure to the site of bleeding.15 A popular dissolvable pack is
Floseal which is a topical gelfoam and thrombin slurry. Much like with applying clamps
or pressure, there is no standard wait time to stop the bleeding for nasal packs. Some of
the literature recommend a 10-minute wait time while others state 10 to 30 minutes.14,15,25
If successful, nasal packs are removed from the nose at home or at a follow-up visit in the
ER 1-2 days after placement. However, if bleeding continues, the next step is to consult
with an Otolaryngologist - Head and Neck Surgeon (also commonly known as ENT).7
There are certain cases where nasal packing will not be sufficient to stop the bleed, and
the patient may need surgery. Although these methods are outlined in the literature,
healthcare practitioners may navigate through the algorithm in variable routes to control
the bleed prior to referring to a specialist.

1.4 Nasal Packs
Historically, the original non-dissolvable nasal packing was Vaseline gauze. Gauze strips
impregnated with Vaseline are layered into the nasal cavity to apply pressure to the site
of bleeding. There is no expansile property to the gauze, and this frequently resulted in
additional trauma to the nasal cavity. Over the last century, different types of nasal packs
have been introduced that are much easier to insert/remove and are much more

6

comfortable for the patient. The best type of nasal packing is heavily debated in the
literature. A myriad of different shapes, sizes and materials have been used for nondissolvable nasal packs. Choosing the best nasal pack requires comparisons on efficacy,
patient comfort and cost-effectiveness.

1.4.1 Rapid Rhino and Merocel
Merocel is a popular brand of non-dissolvable nasal pack made up of polyvinyl acetate.
This pack is essentially a compressed sponge, which increases in size when inserted in
the nose. The pressure of the expanded Merocel in the nose is used to stop a bleed and
prevent the occurrence of a new rebleed. Merocel is one of the more popular nasal packs
to utilize in hospitals. It is not only effective, but also relatively cheaper.
Rapid Rhino (non-dissolvable pack) is an inflatable balloon designed with selflubricating properties and a carboxymethylcellulose covering for clot stabilization. It is
available in four different sizes both with and without a breathing port for adults
experiencing anterior epistaxis. The Rapid Rhino is a high volume and low-pressure
combination that is designed to allow for more comfort for patients and to better contour
to patient anatomy. A 2017 systematic review comparing 27 articles related to nondissolvable nasal packing in both anterior and posterior epistaxis patients found Rapid
Rhino to be the most comfortable for patients.26

1.5 Thesis Objective
While Rapid Rhino appears to be more comfortable for patients, Merocel is still used in
many hospitals. One of the main reasons Merocel is a popular choice of nasal packing in
the hospitals is because it costs less than Rapid Rhino. However, there are very few
studies that examine the economic impact of nasal pack choice.26 Other variables that add
costs to hospital care and ER visits are often not thoroughly examined.
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One important variable influencing the economic cost of nasal packing is rebleed rates.
While the upfront costs of Merocel may be cheaper than Rapid Rhino it is difficult to
conclude that Merocel is less costly compared to Rapid Rhino. Rebleeds cause patients to
return to the ER more frequently which incurs costs for the hospital through costs for
labour, costs for removing nasal packs and costs for preventing the new bleed. The
current literature looking at rebleed rates for Merocel and Rapid Rhino tend to have a
very small sample size and no clear follow-up times.26-39 The small sample size makes it
difficult to conclude which nasal pack is more effective in terms of preventing a bleed.
There is some heterogeneity in follow-up times, these can range from management of
initial bleed in the ER or up until three months after the initial bleed.11,26-39 This makes it
difficult to combine data from different studies to conduct a meta-analysis. There are only
six studies that include both Merocel and Rapid Rhino. Four of these studies only
measure initial management of a bleed or right after a scheduled removal of a nasal pack,
and two studies do not state how many patients received Merocel vs. Rapid Rhino.32,35-39
Based on limited data in the literature, Merocel tend to have a higher rate of rebleeds
resulting in higher overall costs. Only one study compares Rapid Rhino and Merocel
directly to each other in terms of costs, and this study focus on inpatient admission costs
for epistaxis in Ireland.32
The primary objective of this study is to compare total costs of Merocel and Rapid Rhino
in the ER setting using a two-week follow-up period. The hypothesis is that Rapid Rhino
may have reduced total costs, due to a lower rate of rebleeds. Rapid Rhino is more
comfortable for patients and has properties that help with clot stabilization. Both these
factors should contribute to preventing patients returning to ER with a rebleed event.
To test our hypothesis a retrospective study was conducted for the year 2018 using adult
patient medical charts from the emergency rooms in London Health Sciences Centre
(LHSC) -- Victoria and University Hospitals in London, Ontario. Both hospitals currently
utilize Merocel as their nasal pack of choice. In 2018, Rapid Rhino was under evaluation
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at University Hospital for a trial period for the first six months of the year. Merocel was
utilized in both University and Victoria hospitals year-round. Therefore, for the first six
months at University hospital, physicians could choose between utilizing Merocel or
Rapid Rhino. Costing analysis was undertaken from two perspectives: LHSC hospitals
and provincial health care system. The hospital perspective captures the burden of paying
for costs of hospital employees, material costs, costs for the overhead and costs related to
upkeep for the hospital. One limitation of the hospital perspective is that it excludes
physician billings, which are paid by the Ontario Ministry of Health. The provincial
health care perspective captures costs incurred by hospitals and physician billing costs. A
two-week follow-up was chosen as rebleeds outside of this timeframe are uncommon and
would not be considered a failure of the initial management strategy; indeed, a recent
study assessing rebleed rates for Merocel based in Ottawa, used a similar timeframe.11
This analysis will contribute information to the hospital’s management team on whether
to change the nasal packs to Rapid Rhino. Even if there is no difference between the costs
of Merocel and Rapid Rhino after accounting for the rebleed events, the hospital may still
decide to switch to Rapid Rhino for an improved patient experience.
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Chapter 2
2 Literature Review
2.1 Epistaxis
Epistaxis is one of more frequent reasons behind otolaryngology emergencies.1 When a
patient presents to the ER with a nosebleed, physicians ideally attempt conservative
management first. This includes, if the bleeding site can be visualized, silver nitrate to
chemically cauterize the area of bleed.2 Other interventions such as tranexamic acid,
epinephrine can be used as either an alternative to silver nitrate or in conjunction with it
to manage a bleed.3-4 These interventions should be ideally attempted first but are not
always before the more invasive method of nasal packing is considered. Nasal packs can
be dissolvable, (e.g., Surgifoam, Surgicel, and Floseal) or non-dissolvable (e.g., BIPP
packs, Rhino Rockets, Merocel or Rapid Rhino).5 Merocel is popular in many hospitals
due to their low cost when compared to other nasal packs. Rapid Rhino is a newer nasal
pack that is designed to be more comfortable for patients, but it is also more expensive
than Merocel. However, the overall costs associated with nasal packing is more than just
the direct cost of the pack itself. Rebleeds increase patient visits to the ER, thereby
incurring additional costs. Furthermore, when recommending a nasal pack, patient’s
comfort needs to be taken into consideration as well. To fully understand the impact of
nasal packs, efficacy on preventing rebleeds, comfort level for patients when utilizing
these nasal packs and its economic impact to be analyzed. A systematic review from
2017 concluded that Rapid Rhino appeared to be the most comfortable non-dissolvable
nasal pack, yet Merocel is routinely used in hospitals due to its low price.5 Therefore, the
primary focus of the literature review will be to assess the current evidence on efficacy
and costs of the two nasal packing materials: Rapid Rhino and Merocel.
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2.1.1 Search Strategy
EMBASE and PubMed were used to search using the keywords ((epistaxis) AND
(human)) AND (tampons) OR ((epistaxis) AND (hospital costs)) OR ((epistaxis) AND
(emergency department)) to provide a comprehensive list of studies on Merocel and
Rapid Rhino. Figure 2.1 describes the search strategy for these databases. References
from these articles were searched for additional articles and google scholar was used to
identify any missing articles.
The inclusion criteria were:
1) The nasal pack Rapid Rhino, Merocel or both must be part of the study
2) Adult anterior epistaxis patients should be included in the study
3) The study must measure one or a combination of the following.
a. Patient’s discomfort
b. Rate of rebleeding
c. Previous data on patients’ discomfort or rebleed rates were used to
conduct a cost-analysis.
4) Randomized and non-randomized studies were both included
The exclusion criteria were
1) The full text of the article cannot be found
2) If the language the text was written in was non-English
3) The paper was descriptive commentary only
4) The focus on the study was post-operative patients
This search was conducted from June 2021 to September 2021. Initially there were 1416
articles found, out of those 1395 articles were removed due to duplicates, and application
of the inclusion/exclusion criteria to the abstracts. After 21 remained, and for 2 of these
articles the full text could not be found. One article was a descriptive commentary from a
textbook on the current state of epistaxis management. Five articles were excluded
because on full-text review the patients had not received Rapid Rhino or Merocel or it
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2.2 Rebleed Rates
2.2.1 Merocel
Van Wyk et al. conducted a retrospective review of a 2004 ER protocol implemented in
ERs in the United Kingdom.6 In this study, 62 patients were packed with Merocel
initially. Out of these 62 patients, 16 (26%) required admission into the hospital during
initial visits and 46 patients were discharged with Merocel inserted.6 The study found that
about 15% (7/46) of patients discharged with Merocel experienced a rebleed within 3
days after packing.6 This study had no comparable interventions to Merocel. In Ottawa,
Newton et al. conducted a retrospective review of medical charts from January 2012 to
May 2014 in an ER at the Ottawa Hospital.7 They were interested in evaluating patient
rebleed rate within 2 weeks after discharge from the hospital.7 Patients using Merocel had
a 26% (24/92) rebleed rate. The comparison group in this study was silver nitrate, no
treatment, other packing, “other” and nasal clips. Out of all these interventions only
“other packing” may be comparable to Merocel, since nasal packing is generally utilized
after no treatment, silver nitrate, “other” interventions and nasal clips have failed. The
“other” packing group was most comprised of Vaseline with a mixture of other nondissolvable nasal packs. Patients using “other nasal pack” had about a 42% (19/45)
rebleed rate.7 While there was no “control” group in this study silver nitrate was directly
compared to Merocel. This resulted in the study concluding that silver nitrate had lower
rates of rebleed with a odds ratio of 0.694 (95% CI: 0.364–1.322). This difference was
significant with a p-value = 0.27.7
A retrospective review of hospital admissions in the UK in from March 1994 to March
1995 found that Merocel successfully controlled 92% (76/83) of bleeding during the
initial visit.8 However, this study did not have a comparison group or follow-up data to
study rebleed events. Murray et al. conducted a randomized control trial from July 1,
2015 to July 1. 2017 at University of Alberta Hospital and Royal Alexandra Hospital.
They focused on patients with persistent epistaxis and compared Floseal (a topical
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gelfoam and thrombin slurry) to a control group comprising of Merocel and Vaseline
gauze.9 Floseal as mentioned before is a dissolvable packing material that acts more as a
hemostatic matrix rather the applying tamponading pressure like Merocel. While they are
both nasal packs, they are not exactly comparable. Persistent epistaxis was defined as the
failure of a physician to manage previous epistaxis, but the patient had to have a failed
management for longer than 48 hours.9 This study only included patients that were not on
anticoagulants (except for aspirin). Out of the 26 total participants, 13 were treated with
Floseal and the 13 treated with the controls (Merocel and Vaseline gauze).9 Out of the 13
patients in the control group 10 received Merocel, however, it is unclear how many of
the rebleeds reported were in patients packed with Merocel.9 Initially about 77% (10/13)
of patients treated with Floseal and 85% (11/13) of patients treated with Merocel, or
Vaseline gauze had a rebleed right after the treatment. There were 15% (2/13) of patients
requiring admission into the hospital from the Floseal group, and 46% (6/13) of patients
required admission in the Merocel and Vaseline gauze group.9 For re-occurrence of
bleeding at 48 hours, 77% (10/13) of patients treated with Floseal had a rebleed and 69%
(9/13) of patients treated with Merocel and Vaseline gauze had a rebleed.9 Finally there
was a 15% (2/13) recurrence of rebleeds for the Floseal group and 46% (6/13) recurrence
for the Merocel and Vaseline gauze group within 30 days after initial packing.9

The oldest randomized control trial measuring patient’s rebleed rates for Merocel was
conducted between March 1, 1994 to July 14, 1994 at Northwick Park Hospital in
Middlesex, UK.10 This trial compared Merocel to Bismuth subnitrate and Iodoform paste
(BIPP).10 There were 49 patients total and the authors counted each side as nasal cavity
packed. There were 27 nasal cavities packed with Merocel and 28 nasal cavities packed
with BIPP. Out of the 27 nasal cavities packed by Merocel, 25 (93%) were successfully
controlled with nasal packs initially.10 For BIPP, 24 were packed successfully out of the
28 (86%) nasal cavities.10 Akkan et al. conducted a randomized control trial in one
hospital ER from May to August 2018.11 They had 3 treatment groups, tranexamic acid
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with compression (TXA), nasal compression and Merocel packing.11 There were 45
patients in each group. The study measured cessation of a bleed within 15 minutes of the
intervention being used and any follow-up bleeds at 24 hours.11 Merocel was successful
in stopping about 93% (42/45) patients bleed within 15 minutes of application. After 24
hours Merocel was successful in preventing a rebleed for 73% (33/45) of patients.11
Simply applying pressure and utilizing TXA cannot be compared to Merocel, as stated
before Merocel is nasal pack and is therefore often used after initial inventions like
pressure and TXA have failed. However, the authors reported the rate of rebleeds for
patients that received TXA and nasal compression (summarized in Appendix B).
Mehanna et al. conducted a prospective study with a 24 hour-follow up after pack
removal.12 A total of 50 patients were included in the study, if they needed nasal packing
and were admitted into the otolaryngology ward. Of these patients, 25 received Merocel,
17 received Vaseline gauze, 2 had BIPP inserted, and 6 packs were not recorded.12 In this
study, 10 patients had recurrent epistaxis after pack removal, but the study did not specify
which nasal pack the patients had received before rebleeding.12
Abdelkhalek et al. conducted a prospective trial with patients that presented with
epistaxis at the emergency or ENT departments of Al-Azhar university hospitals between
April 2021 to January 2022.13 They measured if bleeding was stopped initially and
monitored patients weekly for 3 months for signs of rebleeds.13 In this study 30 patients
received Merocel and 30 patients received a Merocel/Surgical wrap. Initially 24/30 (80%)
of the patients with Merocel alone did not rebleed. 13 In contrast, 29/30 (97%) of patients
that received the Merocel/Surgical wrap successfully stopped their bleeding.13 Within 3
months 22/30 (73%) of the patients in the Merocel group did not experience a rebleed,
while 28/30 (93%) in the Merocel/Surgical wrap did not experience a rebleed.13
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2.2.2 Rapid Rhino
Singer et al. conducted a randomized control trial that took place in one urban ER and
one suburban ER in the US.14 This trial compared Rhino Rockets (equivalent pack to
Merocel, except with an introducer) to Rapid Rhino.14 The patients returned for packing
removal within 3-days, and any rebleeds during removal were noted.14 If patients
required another nasal pack to replace Rapid Rhino or Rhino Rocket during the initial or
pack removal visit, this was considered a rebleed. Rapid Rhino had a 90% (18/20)
success rate in initially stopping a bleed. Similarly, Rhino Rocket had a 90% (18/20)
success rate initially. This left 18 patients in each group discharged with a nasal pack
inserted. Out of 18 patients in each group whose bleed was initially controlled by the
nasal packs, 1(6%) patient using Rapid Rhino experienced rebleed while 7(39%) patients
using Rhino Rocket had bleeding on pack removal.14
Khan et al. compared the efficacy of different nasal packing on patients who had
presented with epistaxis at the Department of Otolaryngology – Head and Neck Surgery,
Freeman Hospital, Newcastle, UK.15 The study included adult patients who had epistaxis
on the year 2012 between November and December. Out of the 101 patients, 49 had
anterior epistaxis.15 Rapid Rhino and Floseal packs were used for secondary care, after
conservative measures or other nasal packing had failed. In this study both Rapid Rhino
and Floseal were successful in managing bleeding (100%).15

2.2.3 Merocel vs. Rapid Rhino
There are multiple studies that compare these two packs directly to each other. Badran et
al. conducted a randomized control trial in ENT ER comparing Rapid Rhino and Merocel
in terms of recurrence of bleeding in patients with anterior epistaxis from February 2002
until June 2002.16 Patients were included into the study if they were 16 years and over
and they had uncontrolled epistaxis after attempting cautery/ pressure for more than an
hour.16 This prospective trial had 52 patients which randomly allocated 26 patients in
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each trial group.16 However, data were lost for 1 person in each group resulting in
Merocel and Rapid Rhino having 25 patients each. The study noted how many patients
required repacking or were sent to surgery (theatre) during their initial visit after the first
nasal pack failed. In this study, 6/25 (24%) of patients in the Rapid Rhino group had to be
repacked or taken into the theatre, whereas 7/25 (28%) patients out in the Merocel group
were repacked or taken into the theatre during their initial visit.16 When the pack was in
place and removed (24-72 hours later), the degree of bleeding was noted from a scale of 0
to 4. Where 0 indicated no bleeding and 4 indicating that the nasal tampon did not control
the bleed.16 For bleeding during pack insertion in the initial visit, Merocel had a score of
1.6 and Rapid Rhino had a score of 1.3.16 After the pack was removed, Merocel had a
score of 1.4 and Rapid Rhino had a score of 1.3.16 These results indicate that there was
slight bleeding during the initial and follow-up removal for both Rapid Rhino and
Merocel.
Another prospective randomized control trial compared Rapid Rhino and Merocel in
terms of success at controlling a bleed during the initial visit.17 In this study, patients over
16 presenting with epistaxis over a two-year period at Otolaryngology Department at
Addenbrooke’s Hospital, Cambridge, UK were included.17 In this study, 16/21(76%)
patients were successfully treated with Rapid Rhino compared to 17/21 (81%)
successfully treated with Merocel during their initial visit to the hospital.17
Lau et al. conducted a retrospective review where they included 90 patients who had
nasal packing at University Hospital Aintree, UK between March 2007 and March 2012.
They then checked medical charts to see which patients had recurrent bleeding at 72
hours.18 From this, 8 patients who had Rapid Rhino returned with recurrent bleeding and
6 patients who had Merocel returned with recurrent bleeding.18 The number of patients
who received Rapid Rhino or Merocel were not clarified.18 Khan et al. utilized Merocel,
Rapid Rhino and Floseal in the initial treatment of anterior epistaxis.15 In this study, one
patient received Rapid Rhino and was treated successfully during the initial visit, one
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patient received Floseal and required cautery afterwards, and only 3/13 (23%) of patients
were successfully treated by Merocel.15
Iqbal et al. conducted a systematic review of the literature in 2017 on the efficacy of all
dissolvable and non-dissolvable packs for both anterior and posterior epistaxis.5 They
found that Rapid Rhino and Merocel had the same rate of rebleeds, but these results
included both anterior and posterior epistaxis patients pooled together.5
Keane et al. looked at the management of epistaxis in a single secondary referral center in
Ireland from 2009 to 2012.19 They had a total of 446 patients of which 434 were included
in the study as they had spontaneous epistaxis. In the study about 83.4% of patients were
managed by packing or cautery.19 The study grouped patients that had cautery with
patients that had packing. Patients were packed by Rapid Rhino, Merocel, Vaseline
gauze, Floseal or BIPP.19 The study noted that 34 patients came back with recurrent
bleeding that had nasal packing, although the follow-up period is not clearly stated, the
implied assumption was that the authors meant a recurrence over the 4-year study
period.19
Lastly, Karia et al. conducted a prospective trial comparing patients that received Rapid
Rhino or Merocel in the ER between March 2020 and March 2021.20 They measured
rebleeding at scheduled pack removal 1-2 days after initial visit to the ER. Out of the 56
patients that received Rapid Rhino, 6 had a rebleed (11%) during their pack removel.20
Out of the 24 patients that received Merocel 1 (4%) had a rebleed during their pack
removal.20 The study found no-significant difference between Merocel and Rapid Rhino.

2.2.4 Summary
Overall, many of the studies assessing rebleed rates for Merocel and Rapid Rhino have
different follow-up times. Some studies only measure the initial control of a bleed, and
others measure a rebleed within 24 hours to 3 months. Due to this inconsistent follow-up
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timeframe, it is difficult to assess the rate of rebleeds for a nasal pack. In terms of
Merocel rebleed rates, the nasal pack had a lower rate when compared to BIPP and
Vaseline gauze7,10 Merocel had a higher rate of rebleed in contrast to Floseal during the
initial visit, had a higher rate of patients admitted to the hospital and higher rate of
bleeding at the 30-day mark.9 This study had a small sample size, and Merocel was
combined with Vaseline gauze so it is difficult to assess how many of the rebleeds came
from patients packed with Merocel. Various studies had inappropriate or no comparator
groups to Merocel, and did not state how many patients received Merocel or how many
patients that received Merocel returned with a bleed.6,8,11-12 Rapid Rhino has even fewer
studies relating to anterior epistaxis and these studies have low sample sizes.14-15 Rapid
Rhino appears to have a similar rate of rebleed in contrast to Floseal and lower rates of
rebleed compared to Rhino Rocket.14-15 The study comparing Floseal to Rapid Rhino has
a very small sample size.15 When looking at studies comparing Rapid Rhino to Merocel
directly, it appears that Rapid Rhino and Merocel have similar rates of rebleed during the
initial visit or during scheduled packing removel.16-17,20 Only two studies that included
Rapid Rhino and Merocel had a follow-up period beyond cessation of initial bleeding
(not including bleeding during scheduled follow-up packing removal visit) but these
studies did not indicate how many patients received Merocel or Rapid Rhino.18-19

2.3 Comfort
2.3.1 Merocel
Corbridge et al. measured patients comfort level during insertion and removal of packs.10
A 10-point visual analog scale was used to measure pain level for patients that had BIPP
and Merocel packing. Patients that used BIPP had a decrease in patients’ pain level by a
score of 1.4 during insertion compared to patients that had Merocel.10 As well, pain levels
for Merocel during removal was on average rated a 3.5 compared to BIPP at 2.8.10
Pringle et al. measured patients comfort level using Merocel along with rebleed rates.8
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Out of the 83 patients packed with Merocel, 34 completed the 10-point visual analog
scale questionnaire.8 The mean scores for patients’ comfort during insertion was 5.3,
when the pack was in the patient’s nose it was 2.9 and during removal it was 3.4.8
Murray et al. measured patients’ pain during insertion, duration of treatment and removal
of the nasal tampon using a 10-point visual analog scale.9 They compared Floseal to a
“packing group” that contained Merocel/Vaseline gauze. For insertion, patients that
received Floseal scored their pain at 2.4 to Merocel/Vaseline gauze 7.8.9 During when the
pack was in place, patients using Floseal scored their pain a 0.5 to Merocel/Vaseline 4.5.
Finally, during removal patient’s scored Merocel/Vaseline a 3.9 to Floseal 0.9 The
authors found a significant difference at the 5% level in the pain level for insertion,
treatment, and removal felt between the experimental groups.9
Abdelkhalek et al. measured pain during insertion, for patients that received Merocel or
Merocel/Surgical wrap. Patients were classified as experiencing “Mild”, “Moderate” or
“Severe” pain.13 Chi-square analysis resulted in there being no difference between
Merocel and Merocel/Surgical wrap at the 5% level for the number of patients classified
under each category of pain.13

2.3.2 Rapid Rhino
Singer et al.14 measured patient’s discomfort level when the pack was inserted and
removed using a visual analog scale from 1-100. Patients on insertion of Rhino Rocket
felt on average a discomfort level of 48 (95% CI: 34 to 61).14 In contrast patients on
Rapid Rhino felt 30 (95% CI: 18 to 41) of pain on insertion.14 During removal the pain
for patients with Rhino Rocket was 23 (95% CI: 13 to 33) to Rapid Rhino’s 11 (95% CI:
1 to 21).14
Hettige et al. conducted a prospective trial in a clinic in the U.K where they recruited 15
adults to gauge their comfort level when using Rapid Rhino.21 Out of the 15 adults, 3
dropped out of the trial, leaving 12 individuals in the study. Two Rapid Rhino were
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inserted bilaterally, where one pack was attached to a manometer to gauge pressure.21
The researchers randomly inflated one side, and then inflated the other. Patients’ comfort
was measured on a visual analog scale from 0 to 10 at different nasal pressure (the
detailed results presented in the Appendix B). In summary, patients from 40 mmHg to 60
mmHg ranked their pain less than 2 on the scale for both unilateral and bilateral
packing.21 From 80mmHg to 100mmHg, patients rank their pain from 2.7 to 3.6.21 While
patients ranked their pain for 140mmHg to 160mmHg 4.1 to 5.0.21 The researchers
acknowledged that the measured pain levels from 140 mmHg to 160 mmHg may not be
valid as Rapid Rhino is not meant to be used at these high-pressures.21 Overall, from
40mmHg to 100mmHg patients tend to find Rapid Rhino tolerable.

2.3.3 Merocel vs. Rapid Rhino
Badran et al.16 compared patients’ pain level at insertion and removal for Rapid Rhino
and Merocel using a 10-point visual analog scale. A significant difference (p = 0.01) was
observed for insertion where patients rated Merocel a 6.9 and Rapid Rhino a 5.16 Pain felt
at removal was significant (p = 0.05) since patients rated Merocel a 4.6 and Rapid Rhino
a 3.4.16 Moumoulidis et al.17 conducted a prospective randomized control trial which
compared Merocel and Rapid Rhino in terms of comfort during insertion, course of
treatment and removal using a 10-point visual analog scale. For pain during insertion,
Rapid Rhino (3.9) outperformed Merocel (6.5) significantly (p < 0.001).17 Pain felt
during treatment was not significantly different between the two packs.17 Finally for pain
felt during removal, Merocel had a score of 5.0 and Rapid Rhino has a score of 2.5, a
significant difference between the two packs (p < 0.001).17 Iqbal et al.5 in their
systematic review found that Rapid Rhino was the most tolerable for patient comfort.
However, they included posterior and anterior epistaxis and there are more studies in
relation to posterior epistaxis and Rapid Rhino.
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Karea et al. also measured patients comfort for Rapid Rhino and Merocel during
insertion, while the nasal pack was inserted and at removal.20 They utilized the WongBaker FACES pain test, a scale from 0 to 10, with 0 indicating no pain. Patients felt no
significant difference in pain at the 5% level during insertion and while the pack was
inserted.20 However, during removal Rapid Rhino had a pain scale of 4.05 to Merocel
6.09 (p=0.02).20

2.3.4 Summary
Merocel appears to be less comfortable than other nasal packs.9-10 Meanwhile, Rapid
Rhino appears to be more comfortable to other nasal packs, including Merocel.5,14,16-17,20
However, there were few studies that measured patient comfort and some studies had no
comparators.8,21 Studies measuring patient comfort often used a visual analog scale,
which is a subjective indicator of pain level, and it is difficult to measure pain levels
without bias. Measuring a patient’s overall health related quality of life would be a more
suitable outcome to assess. This is because improvement in the pain domain could affect
other domains of the health-related quality of life. Moreover, if we wanted to conduct a
cost-effectiveness analysis for nasal packs, we need to take into consideration how a
patient’s overall quality of life would change in response to different interventions for
epistaxis management. However, with most studies using the same 10-point scale it
allows for comparison between studies.

2.4 Cost Analysis
Limited literature exists on cost-effectiveness, or cost analysis of nasal packs. An
economic evaluation compared Floseal to other types of packing for anterior epistaxis
patients from the Canadian health care perspective.22 This study concluded that Floseal
was more cost-effective compared to other packings, including Merocel for patients with
anterior epistaxis.22 Patient costs were obtained from the Ottawa Hospital Data
Warehouse and physician fees were gathered from the Ontario Schedule of Benefits for
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Physician Services.22 They utilized a Markov Model in this study, using the three
transition rates of “well”, “recurrent bleeding” and “dead.” These transition probabilities
were based on the results of Mathiasen and Cruz.23 Mathiasen and Cruz conducted an
RCT where there were 35 patients in the Floseal and 35 patients in the “control group”.23
The control group is composed of patients with any nasal packing depending on the
physician’s treatment, for example the physician could choose to use Merocel, Rhino
Rocket, gauze or any other pack they deem appropriate.23 Since Mathiasen and Cruz,23
did not clarify what nasal packs were used in the control group, the efficacy of Floseal is
difficult to quantify relative to another specific pack. Furthermore, health utilities for
patients experiencing epistaxis were assumed to be the same as the general population in
Canada.22 However, patients experiencing epistaxis would most likely have a lower
health utility than the average Canadian, as they are known to have comorbidities like
hypertension and conditions requiring anticoagulation.22
A recent study by Nithianandan et al. used Newton et al. retrospective review on anterior
epistaxis patients to conduct a cost analysis. The analysis included direct costs and
utilized the Ottawa Hospital Data Warehouse to determine patient costs, while accounting
for any recurrence of bleeding into the costs.24 The case-costing system within the Ottawa
Hospital Data Warehouse provides estimated cost information on patients diagnosed with
anterior epistaxis. Generalized linear models were utilized to analyze relationships
between treatment and cost while adjusting for confounders.24 Merocel incurred the
highest median cost $763.98 (IQR: $632.25, $830.230).24 The second highest was
Vaseline gauze packing $723.12 (IQR:658.94, $810.84).24 However, there was no
significant difference between Merocel and Vaseline gauze (p=0.90).24 The other
treatments in this cost-analysis were a nasal clip, no treatment, other treatment (topical
TXA or similar interventions) and silver nitrate. These interventions as described before
are often used before Merocel, to stop bleeds and because of this they cannot be directly
compared to Merocel. Moreover, Merocel was compared to Vaseline gauze in this study,
and these two interventions can be compared in terms of the costs but based on other
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factors such as ease of use, rebleed and discomfort would not have clinical equipoise for
most clinicians. Furthermore, recurrence of a rebleed was defined as 14-days but the total
costs in the Nithanandan et al. were based on a 30-day period after the patient’s initial
visit.24 If after 14 days any bleed is considered a new bleed, then any costs after 14 days
incurred by the patient cannot be attributed to the initial intervention.
Murray et al. conducted their own economic analysis based on their prospective
randomized control trial.9 They conducted this analysis using the societal perspective, but
also included a separate analysis for the Alberta Health Services perspective. The initial
costs of emergency rooms visit (included physicians costs) were excluded as they were
assumed to be similar in both the Floseal and control group.9 Costs for surgical fees,
physician’s fees, medical ward fees, outpatient fees, and nasal packing fees were
included. Costs related to patient productivity loss from missed time at work were also
calculated.9 Costs were calculated up to 30-days after admission since in their trial they
measured rebleeds up until a month after the initial visit.9 ICERs were estimated (costs
for rebleeds avoided), for both the hospital and societal perspectives.9 For a single-payer
system, Floseal was found to have a mean cost savings of about $1567.61 per patient and
from the societal perspective, a mean cost-saving of about $2233.369 per patient.9 This
study had both anterior and posterior epistaxis patients included, so gauging costs for
anterior epistaxis patients only is not possible.9 They also had a mix of gauze and
Merocel in their control group with only 13 patients total (10 Merocel, 3 gauze).
However, it is not clear how many patients returned to the hospital with a bleed that
received Merocel initially and patients requiring admission were the main reason why
from the hospital perspective Floseal appeared to be cost-effective.9 However, when
looking at the 6 patients that required admission in the Merocel/Vaseline gauze group it
appeared that 1 patient was admitted due to pneumonia and 1 patient required cardiac
surgery. While, the study did not consider nasal packs as independent indications to
admission, the surgical/medical ward costs associated with these 2 patients would be
higher than regular patients.9 Therefore, these patients could increase costs associated
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with using Merocel/Vaseline gauze when in reality it was probably due to other
underlying condictions.9
Keane et al. measured average length of stay for inpatients between 2009 to 2012.19 They
then took the average cost of overnight inpatient stays and calculated the average cost for
overnight inpatient stay for each treatment.19 Then they added the costs of the direct
material related to each treatment to the costs for inpatient stay and calculated total cost.
In the non-dissolvable nasal packs, Merocel was the cheapest at (€3593.99), then Rapid
Rhino (€3613.83) and then BIPP packs (€3617.83).19

2.4.1 Summary
There are few cost analysis studies and cost-effectiveness analysis studies for epistaxis in
the literature. The main issues with cost-effectiveness analysis studies are the availability
of meaningful effectiveness data. The costs in most of the studies were often
comprehensive, which include the cost of the initial treatment and any subsequent
follow-up treatments, and hospital and overhead costs. On the other hand, the efficacy
data were either missing or not meaningful for the purpose of cost-effectiveness analysis.
The efficacy data were based on studies with information on recurrence of rebleeds, but it
is better to capture this in costs rather than effectiveness. Although rebleeds are a valid
way of gauging effectiveness of the initial treatment, patient quality of life is the most
important element in a formal cost-effectiveness analysis. A few cost-analysis studies
published in the literature focused on inpatient costs or have costs that are not meaningful
for comparing nasal packs.19, 24

2.5 Gaps in the literature
Studies examining rebleed rates had a small sample size and recurrence of rebleeds seem
not to be a common outcome. Usually, data are collected from different studies and
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combined to conduct a meta-analysis. This is difficult for rebleed rates as the definition
for recurrence of a bleed varies through the studies conducted. As seen in this review, the
recurrence of a bleed can be measured at a range from initial management of a bleed to 3
months following discharge. Patients’ bleeding might have occurred within hours of
leaving the hospital up until the last day of the month depending on the study follow-up.
Since rebleed rates are usually measured as dichotomous variables rather than time-to
event, this creates more difficulty in assessing exactly where patients rebleeds occurred in
between studies. This variability makes combining individual study data for a metaanalysis challenging. Currently there is no good quality study that assess the rebleed rate
of Merocel and Rapid Rhino together with a follow-up period beyond the initial treatment
of a bleed or during a scheduled pack removal. Only six studies included in this literature
review assessed rebleeds for both Merocel and Rapid Rhino together.15-20 Four of them
did not have a follow-up period for assessing recurrence of bleeds excluding any bleeding
during scheduled pack removal, and the other two did not calculate the number of
patients packed with Rapid Rhino or Merocel when discharged.15-20 There are few studies
that conduct a cost analysis for anterior epistaxis, and there is only one study that
compares Rapid Rhino to Merocel directly.19 This study calculated costs associated with
inpatient admissions.19 Two studies that assessed costs associated with Merocel packs,
grouped other nasal packs with Merocel, making it difficult to ascertain what costs are
directly associated with Merocel.9,22 Finally, one study from Ottawa assessed costs of
only Merocel packs defined a recurrence of bleed to be within two-weeks but analyzed
total costs for 30-days after the initial encounter.24 Our study aims to fill this gap by
assessing and comparing directly the rebleeds for both Merocel and Rapid Rhino using a
two-week follow-up timeframe. Indeed, two weeks chosen due to an expert’s opinion and
two weeks have been previously used as a follow-up timeframe for epistaxis in a previous
study based in Ottawa.7 The costs incurred in the emergency room would be calculated,
along with calculating physicians’ costs to provide a hospital as well as provincial health
system perspective.
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Chapter 3
3 Analysis of healthcare costs associated with Merocel or
Rapid Rhino use
3.1 Introduction
Epistaxis can resolve by itself with time. However, some patients with epistaxis require
an intervention by clinicians. Some of these interventions include directed therapy. An
example of this would be cauterising a nosebleed with silver nitrate. Nasal packs, both
dissolvable and non-dissolvable, usually are inserted into the nose to stop a bleed after
failure of initial interventions like cautery via silver nitrate. They are then removed 24-48
hours afterwards. Non-dissolvable nasal packs include Rapid Rhino and Merocel.
Merocel is a popular choice as it is less expensive relative to Rapid Rhino. Rapid Rhino
is more expensive but is proving to be better for patient comfort.1 Researchers have
conducted various studies on the efficacy of Merocel or Rapid Rhino in stopping initial
bleeding and in preventing rebleed visits.2-6 However, these studies have inconsistent
definitions for rebleeds, small sample sizes or the studies tend to group various nasal
packs together making it difficult to assess the efficacy of Rapid Rhino compared to
Merocel. Furthermore, the literature on costs associated with epistaxis interventions are
limited to date. According to a 2017 systematic review on epistaxis management, there is
no robust economic assessment on dissolvable and non-dissolvable packs.1 Without data
on costs, it is hard for studies to provide recommendations on interventions as both costs
and efficacy need to be taken into consideration in evaluating treatment decisions in a
healthcare setting. This is especially true in the Canadian context as there is a singlepayer publicly funded health care system, and the objective is to maximize population
health within constrained resources.

33

3.2 Methods
3.2.1 Study population
A list of patients presenting with epistaxis in the ER was generated from the
administrative departments from both University and Victoria hospitals, containing every
patient encounter over the calendar year 2018. This list also contained “ER time in” and
“ER time out” for each patient in the emergency room. “ER time in” represented the time
a patient had checked into the emergency room, and “ER time out” represented the time a
patient had been discharged from the hospital.
Ethics approval was obtained to retrieve medical charts needed for this study. The
corresponding HSREB number for this study is 119264. This included submitting an
ethics application with a project proposal, data collection tools and details on information
needed from these medical charts. A copy of the ethics application can be found in
Appendix C. Furthermore, Standard Operating Procedures for Clinical Research and the
Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans training
needed to be completed. Hospital mandated trainings, including patient empathy training,
safety training, COVID-19 Compliance with Infection Prevention & Control Practices
were completed. Further training was required for REDCap (Research Electronic Data
Capture) which is an electronic data capturing system hosted on the Lawson network.7
REDCap is a secure, web-based software platform designed to support data capture for
research studies.7 After REDCap training was completed, a platform to host data from the
medicals charts was created on the REDCap software and handed over to the ethics
committee to approve.
After ethics approval was obtained, medical charts were pulled for each adult patient
visiting the ER with epistaxis as the primary diagnosis between January 1, 2018, and
December 31, 2018. To ensure further accuracy, the dates of patient encounters on the
medical charts were cross-referenced with the dates on the generated patient lists, and the
electronic patient record was reviewed to verify any missing data. Patients were included

34

into the study if; they were adults, had a primary diagnosis of anterior epistaxis, and
received Merocel or Rapid Rhino between January 1,2018 and December 31, 2018.
Information on the type(s) of intervention(s) a patient received was retrieved from the
medical charts. The patient’s sex and age were also collected from their respective
medical charts. Additional information, like patient’s use of anticoagulant medication,
and their use of an ambulance to arrive to the ER was also retrieved from the charts.

3.2.2 Variable Definitions
The explanatory variables in this study include sex, age, use of anticoagulant medications
and the use of an ambulance for the initial ER visit. These variables were chosen from
taking into consideration previous literature that indicated that these variables were
potential risk factors for epistaxis incidence and rebleed events, and therefore could
confound the relationship between the nasal pack and total costs.8-10 The use of an
ambulance was not a previously considered a risk factor in the literature, however, using
an ambulance could indicate a more severe bleed which may incur more costs and was
therefore included in this study. Sex was a dichotomous variable representing 0 for male
and 1 for female. Similarly, data on anticoagulant medication and the use of an
ambulance were binary variables representing 1 for presence and 0 for absence. Age and
age-squared were continuous variables. Inclusion of age and age squared could help
provide potential non-linear relationship between age of the patients and total cost.
The first time a patient was packed in the ER with Merocel or Rapid Rhino, this was
included in the data set with 0 representing Merocel and 1 representing Rapid Rhino.
This did not necessarily mean that this was the patients’ first time coming into the ER for
epistaxis treatment. Only 2 patients that received Merocel were repacked with Merocel
after our two-week follow-up window. Therefore, to make the dataset cleaner these
patients were included once. No patient that received Rapid Rhino had repacking with
Rapid Rhino after two weeks.
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3.2.3 Treatment Effectiveness
To gauge initial treatment effectiveness in managing epistaxis, rebleed events were
calculated. A rebleed event was defined as the first rebleed that occurred within 14 days
since a patient had been discharged from the hospital after s/he was packed or if an ENT
was required to provide further intervention during the initial visit after the use of a nasal
pack to manage the bleed. The follow-up period was chosen to be 2 weeks to be
consistent with a previously published study in Ottawa as well as expert opinion.11 For
the expert’s opinion we asked a specialist in epistaxis management about the appropriate
timeframe they would consider a patient returning to the ER as a rebleed. While,
remaining consistent with the literature should not be the only rationale behind the twoweek follow-up period, measurement of rebleeds varies considerably in the literature.1-6,11
Therefore, we reasoned that a combination of an expert’s opinion, plus a previously
published study in a similar setting would justify our 2-week follow-up in the absence of
recommendations and inconsistency in the literature. After 2 weeks, any bleed was
considered a new bleed and could not be attributed solely to the failure of the nasal pack
used in the first ER visit.
As medical charts usually only note if an ENT was consulted, electronic notes were
reviewed to understand what the ENT did if the ENT was consulted during the patient’s
initial visit. This was because at times the ENT is consulted but they provide no further
intervention if the patient’s bleed had stopped. Here, ENT consult fees would still apply
but there is no rebleed, as the nasal pack inserted managed to stop the bleed with a
tincture of time alone.
After, conferring with an expert, it was decided that representations for rebleeds should
be measured as a dichotomous variable (0 for absence, 1 for presence), and costing
information only included the first rebleed after the patient was discharged from the ER
even if there were multiple bleeds within the two weeks. Multiple rebleeds are defined as
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patients returning to the ER for more than 1 rebleed visit after their initial discharge due
to rebleeding within the two-week follow-up period. This was due to the difficulty in
allocating costs for subsequent interventions a patient would receive after multiple visits
as being related to the initial intervention, rather than the subsequent packing or
intervention chosen. From our expert’s opinion, there are a small subset of patients that
have multiple visits within days of the initial interventions regardless of what packing
they received, or these patients come back to the ER for reassurance. In our study only 8
of the 62 patients in Merocel and 2 of the 17 patients in Rapid Rhino had multiple visits.
As only a small subset will have multiple visits and including costs after the first rebleeds
would result in including costs associated with other interventions, only the first rebleed
after discharge was included. A sensitivity analysis excluding patients that had multiple
bleeds was conducted to see if this affected the results. Another sensitivity analysis was
conducted by excluding patients that were classified as a rebleed that required an ENT
consult during their initial visit. Patients that require an ENT consult might have a more
severe bleed, therefore it is important to see if excluding them will change the results. We
also excluded patients that had missing packing removal visit after the initial visit to the
ER to understand if this would affect our conclusions.

3.2.4 Cost Data
Cost analysis was conducted from two distinct perspectives: the hospital, and the
provincial health care system. For both perspectives, costs were divided into initial visit
and follow-up rebleed visit. The initial visit included the first ER visit for Merocel or
Rapid Rhino packing. If the patients came back for packing removal this was also
included in the initial visit encounter as these costs are associated with the initial packing
intervention. Patients that were classified as a rebleed due to needing an ENT to manage
their bleed during the first visit, were included under the initial visit as this happened
during their initial visit. The first rebleed after discharge from the initial ER visit is
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considered follow-up rebleed. If a patient was repacked when s/he experienced a rebleed
and came back for packing removal this was included in the follow-up rebleed costing.

3.2.4.1 Hospital Perspective
For the hospital’s perspective, costing data were obtained from the LHSC case-costing
centre. The data obtained from the hospitals could be classified into direct and indirect
costs from the hospital’s perspective based on the Canadian Patient Costing Database.12
The total cost is the sum of the direct and indirect costs (from the hospital’s view). These
costs include administrative costs, costs for utilities, cost for supplies, costs for materials
used on patients, cost related to the building and costs related to the labour (with the
exception for physician billing).12

3.2.4.2 Provincial Health Care Perspective
For the provincial health care perspective, all physician costs were added to the costs
from the hospital perspective. This was because the province pays for the physician’s
time and any associated billings. An ER physician fee is difficult to calculate as often
they are juggling multiple patients and do not spend the entire time a patient is in the ER
with them. However, physician costs are an important aspect in determining costs
associated with nasal packing. To include physician costs, we consulted an ER physician.
The physician recommended using the “multiple systems assessment billing” found in the
Schedule of benefits.13 The multiple systems assessment billing is when an ER physician
has to examine or take a patient’s history for more than one part or system in their body.13
From the ER physician experience, this billing is usually applied to epistaxis cases on a
community center setting, and can be used to assess physician fees in the ER. The fee for
multiple systems assessments changes depending on weekdays, evenings, nights, and
weekends. The fee is applied when patients are checked into the hospital or in other
words their “ER time-in”. Table 3.1 presents the exact breakdown of the costs.
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There was an additional cost component that need to be included in the provincial health
care perspective: physician billings. This was because physicians could be eligible to
submit billings for preforming any medical procedures that are needed for the patient and
these procedures are billable under the Ontario Schedule of Benefits for Physicians.13 The
first instance of billing was if a physician must cauterise a bleed using silver nitrate. The
second was if they must pack the nose. When a patient failed silver nitrate, and a pack
was put in place, the physician is allowed to bill for both interventions.
Finally, if a consultation by an ENT was needed then additional billings were included.
These billings are typically paid out to the physician by the Ministry of Health. After
conferring with an ENT specialist, there were certain billings that were typically included
for an ENT consult in the ER. ENT have a base-consult fee, and usually bill a “travel
premium”, and a “first person seen premium” when consulting patients in the ER. When
an ENT specialist is consulted, they should be using a flexible endoscope to examine the
patients’ nasal cavities. This service has a “scoping fee” attached to it.

ENT consult fee = base consultation fee + scoping fee + travel fee + first person seen
fee.
If an ENT needs to repack or re-cauterize a patient, they can charge the same billing fee
for packing and cauterizing that ER physicians use to the Ministry. If they scope a
patient, pack a patient, or cauterize a patient on what is considered “off-hours” provided
in Table 3.2, they can apply a percentage increase from the regular billings (also reported
in Table 3.2). Since, an ENT is consulted as a last resort, the patient “ER time-out”
(discharge time) was used to assess which billing codes to use.

Table 3.1: Physician’s fees in 2018
Fees
Canadian Dollars

Billing Code
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Balance in baseline characteristics in relation to treatment status was important as the
treatment a patient received was not randomly assigned in this study. Rather, a healthcare
practitioner decided which nasal pack to use for a patient visiting the ER with anterior
epistaxis. However, since physicians had to chose between Rapid Rhino and Merocel
only at University hospital for the first 6 months of the year, the chance of selection bias
via physicians would be lower. Inverse probability weighting regression adjustment
(IPWRA) and Covariate balancing propensity scores (CBPS) were used to calculate
difference in total costs, after accounting for the differences in observed patient
characteristics between the two groups.16-17 Since only cost data for the first rebleed visit
was utilized, a sensitivity analysis was undertaken by excluding patients with multiple
rebleeds. A sensitivity analysis was also conducted for patients that had a rebleed due to
requiring an ENT specialist to manage their bleed during their initial visit. This is
because we wanted to see if the difference in total costs between Rapid Rhino and
Merocel changed when these patients were excluded. Another sensitivity analysis
excluding patients that did not return for packing removal to the hospital was conducted
to assess if our results change. As the standard errors at the second stage cannot be
independent of the first-stage regression, bootstrapped standard errors were generated
using 500 iterations. The results are presented in Table 3.12.

3.2.5.2 IPWRA and CBPS Weighting
To rectify issues with treatment status not being randomized (potential selection bias)
inverse probability weighted regression adjustment was used.18 IPWRA uses propensity
scores to balance patient covariates in the treatment and control groups.18 IPW weighting
estimates the chance of receiving treatment by calculating the inverse probability of
treatment and then estimating the outcome based on the new weights.18 Essentially,
IPWRA requires two models, one would be the treatment model, and the other would be
the outcome model. If one model was not specified correctly and the other model is
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correctly specified, the estimator would be consistent, which is known as the doubly
robust property.16 IPWRA was used to estimate the average treatment effect of the treated
(ATT). ATT is the estimate for the average treatment effect on people who actually
received the treatment.16 In other words, it calculates the estimate for all of the population
who received the treatment instead of the control.16 For our study, ATT would measure
the estimate for average total costs for those patients that received Rapid Rhino instead of
Merocel.
Covariate balancing propensity score weighting is another alternative method to calculate
and weight propensity scores. CBPS is a type of propensity score weighting that
optimizes covariate balancing requirement in both the treatment and control groups.17
This is done through calculating the treatment assignment and then treating the
propensity score as a covariate balancing score using a generalized method of moments
framework that combines score conditions and covariate balancing moment conditions.17
CBPS model estimates propensity scores that achieve the best possible balance between
treatment and control groups.17 STATA user written procedure “psweight” was used to
estimate covariate balancing propensity scores. Here, the propensity scores are calculated
using the following logit regression model:
p = invlogit (X ∗ b′ )

In this model, X stands for the vector of matching variables and b depends on the
command given.19 In our case we want to generate propensity scores that will have the
best balance, so STATA psweight uses an internal optimization program to get a “b” that
will help us produce propensity score weights to have the best balance between treatment
and control groups.19 This is why before weighting the IPWRA and CBPS propensity
scores look different.
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3.2.5.3 Treatment and Outcome Model Specifications
In this study, the treatment model was specified using a logit regression. The variables
included in this model were patient’s sex, age, age-squared, anticoagulant medication use
and the use of an ambulance at the initial visit. The chance of selection bias is low in the
study, as Victoria hospital never had a Rapid Rhino option for patients. However, both
Rapid Rhino and Merocel were available from January to June at the University hospital
(Merocel was available year-round). Physicians had some degree of choice between
Rapid Rhino and Merocel during this period at the University hospital. Therefore,
including these covariates in the propensity score model could address selection bias
arising from these variables via treatment selection by the physician.

P(𝑌𝑌𝑖𝑖 = Rapid Rhino| x) =
P(𝑌𝑌𝑖𝑖 = Merocel| x) =

eXβRapid Rhino

1+ eXβMerocel + eXβRapid Rhino

1+ e

1

XβRapid Rhino

+ eXβMerocel

In the above equations, P(Yi) represents the probability of treatment assignment. X refers
to the covariates in treatment selection and βs are regression coefficients specific to
Rapid Rhino or Merocel.
The outcome model was specified as a linear regression. Some of the variables included
in the treatment model were also included in the outcome model. These variables include
the patient’s sex, age (including age-squared), use of anticoagulant medication and use of
an ambulance. These variables were included into the outcome model as well because
they were previously discussed risk factors associated with epistaxis or in the case for
ambulance use could indicate a more severe bleed, resulting in more costs incurred.8-10
Therefore, these characteristics could result in more severe bleeds and greater rates of
rebleeds which could result in confounding the relationship between the nasal pack and
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total costs. The outcome model also had a variable for rebleed occurrence, as patients
who experienced a rebleed would incur more costs. Also, interaction with treatment
status and other variables were included into the regression model as part of the IPWRA
estimation procedure.
𝑌𝑌=β1 ×treat 1 + β2 *age+β3 ×age2 +β4 ×sex+β5 ×medication+β6 ×ambulance+ β7 ×rebleed +
β8 ×treat×age+β9 ×treat×age2 + β10 ×treat×sex+β11 ×treat×medication+β12 ×treat×ambulance
+ β13 ×treat×rebleed+ ε

Healthcare costing data tends to not be normally distributed. That is why generalized
linear models (GLMs) are used to provide alternate comparison, as researchers can
specify family and links to capture skewness in the data.20 In our study, five models were
utilized (square root link/gamma distribution, log link/Gaussian distribution, log
link/gamma distribution, log link/Poisson distribution and identity link/Gaussian
distribution) to evaluate which model fits the data better based on model specifications
tests. We tested if any of the specification tests were rejected at the 5% significant level.
The first specification test would be the Pregibon link test, that checks linearly of
response on scale of estimation.21 The next test is the Modified Hosmer and Lemeshow,
and Pearson’s correlation test which checks for systematic bias in fit on raw scale.21
Finally, the Copas test was used for overfitting and cross-validation.21

3.3 Results
3.3.1 Cohort Description
Initially, 72 patients were classified under Merocel. Electronic medical charts for patients
who had missing packing removal that could not be explained by a rebleed visit to the
hospital were reviewed. From these reviews, four patients were excluded because they
were wrongly classified with receiving Merocel, as their electronic charts indicated other
interventions were utilized such as silver nitrate. Another patient was excluded as this
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was considered a complex patient right after surgery, and therefore had different clinical
circumstances. Two additional patients were excluded due to the lack of case-costing
data. Finally, “pscore” on STATA was used to identify patients that were not within
common support region. Patients are assessed on whether they are in the common support
region depending on their propensity scores which are based on their covariates. In our
case this would be the patient’s sex, anti-coagulation medication usage, age, age-squared
and their usage of an ambulance. This led three patients treated with Merocel that were
out of common support to be excluded. There were 62 patients treated with Merocel
available for analysis. For Rapid Rhino, there was no exclusions. However, Rapid Rhino
was available in one hospital for the first 6 months of the year, so the sample size was
smaller than Merocel (N=17).

Merocel
N=72
Wrongly classified =4
Post-op complicated
patient=1
Case-costing data not
available =2
Excluded for being out of
common support region =3

Merocel
N=62
Figure 3.1: Inclusion and Exclusion chart for Merocel
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perspective. When looking at the provincial heath care perspective, similar patterns
appear with Merocel having a cost of $466.09 per patient (95% CI: $405.57 to $526.61)
in contrast to Rapid Rhino per patients costs of $487.58 (95% CI: $398.92 to $576.24).
Merocel costs $257.26 (95% CI: $310.98 to $402.15) per patient while Rapid Rhino
costs $316.52 (95% CI: $228.19 to $404.85) per patient for the initial visit for the
hospital perspective. For the provincial health care perspective, Merocel costs $356.56
(95% CI: $317.20 to $405.04) per patient in contrast to Rapid Rhino $442.61 (95% CI:
$346.15 to $539.08) per patient during the initial visit. Follow-up rebleed visits costs
were averaged between all patients that received a nasal pack, instead of those who just
had a rebleed. This was because Merocel and Rapid Rhino have different follow-up
rebleed rates (39% vs 18%) which in turn affects costs. Rapid Rhino from the hospital’s
perspective costs $37.02 (95% Cl: -$12.33 to $86.38) per patient in contrast to Merocel
$71.50 (95% Cl: $40.35 to $102.66). From the provincial health care perspective, Rapid
Rhino costs $44.96 (95% Cl: -$12.60 to $102.53) per patient in contrast to Merocel
costing $109.52 (95% Cl $65.95 to $153.10) per patient.

Table 3.5: Descriptive Statistics on Costs for Merocel and Rapid Rhino
N
Mean
Median
SD
Total costs for the hospital perspectives
Rapid
17
$353.54
$367.54
$171.42
Rhino
Merocel
62
$328.77
$276.80
$192.35
Initial costs for the hospital perspective
Rapid
17
$316.52
$283.67
$171.80
Rhino
Merocel
62
$257.26
$231.62
$163.87
Follow-up rebleed costs for the hospital perspective
Rapid
17
$37.02
$0
$96.00
Rhino
Merocel
62
$71.50
$0
$122.67
Total costs for the provincial perspective
Rapid
17
$487.58
$491.24
$172.44
Rhino
Merocel
62
$466.09
$406.02
$238.32
Initial costs for the provincial perspective
Rapid
17
$442.61
$486.85
$187.62
Rhino
Merocel
62
$356.56
$317.90
$179.50
Follow-up rebleed costs for the provincial perspectives

Skew

Kurtosis

Min

Max

0.74

3.02

$88.69

$748.26

0.64

3.04

$23.33

$896.44

1.04

3.81

$88.69

$748.26

1.44

5.84

$23.33

$896.44

2.31

6.44

$0

$290.95

1.78

5.22

$0

$502.28

0.35

3.12

$168.66

$876.71

0.71

3.11

$89.65

$1151.92

0.52

3.11

$142.17

$876.71

1.11

4.48

$89.65

$1004.39
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increase in total costs than patients who did not have a rebleed. This difference was
statistically significant at the 0.1% level (p<0.001).

3.3.3.2 Provincial health care perspective
There is a non-significant difference of $29.10 (95% CI: -$50.15 to $108.35) per patient
between the sex at the 5% level. There is a -$9.82 (95% CI: -$94.97 to $75.33) per
patient statistically non-significant difference between patients who use anticoagulation
medications vs. patients who do not. The estimated confidence interval further indicates
no difference between the two groups. Thus, our sample did not provide evidence that the
costs between men vs. women or anticoagulation usage vs. non-anticoagulation usage
were different. Comparatively, taking an ambulance result in an increase of $99.17 (95%
CI: $1.85 to $196.49) per patient compared to patients not taking an ambulance. This
result was significant at the 5% level (p=0.05). Patients that had a rebleed, had an
increase of $233.81 (95% CI: $149.85 to $317.77) in total costs per patient in contrast to
patients that did not have a rebleed. This was also statistically significant at the 0.1%
level, (p<0.001).

3.3.4 Effects of Continuous Variables and Total Costs
Figure 3.3 shows the marginal effect of age on total costs for the hospital and provincial
healthcare results. From these graphs it was apparent that age has an U-shaped
relationship with total costs. The log-gamma regression for the hospital perspective
predicted that age is associated with decreasing total costs for patients until patients are
53 years old, and thereafter it is associated with an increase in total costs. The log-gamma
model associated age with lower total costs until 56 years old and after it was associated
with increasing total costs. The linear and log-gaussian models for the provincial
perspectives also produced a U-shaped effect, and can be found in Appendix F.
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Figure 3.3: Effects of age and total costs for the hospital and provincial health care
perspectives

3.3.5 Propensity Score based Weighting Results
3.3.5.1 Before Weighting
On initial analysis, the covariates were relatively balanced for patients in relation to
treatment status. The coefficients calculated from chi-square and t-test analysis quantify
the difference of the covariates between the treatment groups, and here all had p-values
are greater than the 5% significance level. The results are presented in table 3.9. The logodds ratios of covariates at baseline are presented in table 3.10. The standard mean
difference (SMD) and variance ratio before and after IPWRA weighting between
Merocel and Rapid Rhino users are presented in Table 3.11. The SMD’s after weighting
for the covariate’s are closer to zero, and the variance ratio’s are closer to 1 than before
weighting. This is an indicator that IPWRA weighting resulted in greater balance in
patient covariates between Rapid Rhino and Merocel.
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Rapid Rhino patients before applying any propensity score weights. This was due to as
previously mentioned applying “pscore” from STATA to assess for common support and
dropping any patient out of the common support restriction. After weighting using
IPWRA and CBPS there is greater overlap between Merocel and Rapid Rhino.

Figure 3.4: Propensity Scores for IPWRA before & after weighting
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The coefficients calculated after excluding ENT consults during the initial visit are
available on the second row of Table 3.12. In contrast to the coefficients calculated on the
first row of Table 3.12 (with ENT patients included), the coefficients calculated after
excluding ENT consult patients were slightly higher. For example, using CBPS
weighting for the hospital and excluding ENT consult patients resulted in a $72.91 (95%
CI: -$5823.82 to $5969.65) not statistically significant difference in costs per patient
(p=0.98) for those patients who received Rapid Rhino. The confidence interval contains
0, indicating there is no difference between Merocel and Rapid Rhino. Including these
ENT consults patients had previously resulted in a coefficient of $61.61 (95% CI: $127.84 to $251.05). Excluding ENT patients for the province healthcare perspective,
concluded that there would be a non-significant difference of $83.37 (95% CI: -$1371.36
to $1538.10) per patient for patients who received Rapid Rhino (p=0.91). The confidence
interval once again includes 0, which means that there is no difference between the two
methods. Including these ENT patients resulted in a coefficient of $78.14 (95% CI: $89.54 to $245.83) previously. When excluding ENT patients for both the hospital and
provincial perspectives, our sample did not provide evidence that costs from using
Merocel or Rapid Rhino are different.

3.3.7.2 Excluding Patients with Multiple Rebleed Visits
Multiple rebleeds were defined as visiting the ER more than once for a rebleed event
during the 14-day following initial discharge. Patients can have multiple bleeds for
various reasons, including needing reassurance, or having different underlying health
conditions. Since, costing-data only included the first rebleed, cost for multiple bleeds
were not captured. Therefore, we are excluding these patients to understand if this
changes the difference in total costs between Merocel and Rapid Rhino. In this sensitivity
analysis, 8 patients from Merocel group and 2 patients from Rapid Rhino group were
excluded. Out of these patients, 7 were male and 3 were female. There were 6 patients on
anti-coagulation medication, and 5 patients arrived via ambulance.
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Row 3 on Table 3.12 has the results for difference in total costs after excluding multiple
visits. Excluding patients with multiple bleeds for the hospital perspective resulted in the
following not statistically significant coefficient: $67.22 (95% CI: -$144.68 to $279.13),
p=0.53. If all the patients were included the coefficients was $61.61 (95% CI: -$127.84 to
$251.05). While the estimated coefficient increases when excluding multiple visits, our
conclusion that our sample did not provide evidence that the costs between using Merocel
and Rapid Rhino are different remains the same. Excluding multiple visits for the
provincial health care perspective resulted in an estimate of $102.17 (95% CI: -$63.19 to
$267.53) which was not statistically significant p=0.23 in comparison to $78.14 (95% CI:
-$89.54 to $245.83) if all patients were included. Once again excluding multiple rebleeds
causes the estimate coefficient to increase but our conclusion that our sample does not
provide evidence that using Rapid Rhino or Merocel results in a difference in costs remains
the same.

3.3.7.3 Excluding patients with Missing Packing Removal for their
Initial Visit
There are patients that did not return to the ER for packing removal after their initial visit.
These patients also did not have a rebleed, so the missing packing removal could not be
explained due to a return visit to the ER where the nasal pack would be taken out. In
Merocel 16 patients and in Rapid Rhino 2 of patients did not return to get their packing
removed. This would lead to lower costs so we excluded these patients to understand if
our conclusions would change. There were 11 men and 7 women excluded from the
analysis. There were 5 patients not on anti-coagulation medications and 7 patients arrived
via ambulance.
The estimated coefficients for average treatment effect on the treated after patients were
excluded due to missing packing removal are available in row 4 of table 3.12. The
estimated coefficients when excluding all patients with missing packing removal are
lower than when all the patients were included (row 1 of Table 3.12). For the hospital
perspective, excluding patients with missing packing removal resulted in an nonsignificant estimate of $46.11 (95% CI: -$217.88 to $310.09), p=0.73. Including all
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patients resulted in a coefficient of $61.61 (95% CI: -$127.84 to $251.05). For the
provincial healthcare perspective, if all patients are included for the provincial health care
perspective, the log-gamma model results in an estimate of $78.14 (95% CI: -$89.54 to
$245.83). These estimates are higher then the non-statistically significant $52.44 (95%
CI: -$109.73 to $214.61) if all patients with missing packing removal patient’s were
excluded, p=0.53. However, our sample still failed to provide evidence that there is a
difference in costs using Merocel or Rapid Rhino, when excluding patients with missing
packing removal.

3.4 Discussion
The mean age of patients reported in our study who received Merocel was 70.11
(95% CI: 66.58 to 73.64) and those who received Rapid Rhino was 65.12 (95% CI: 55.53
to 74.70). The median ages for Merocel were 71 (IQR: 61 to 82) and for Rapid Rhino
was 66 (IQR: 62 to 75). The mean age of 76.1 was reported by Van Wky et al. for his
cohort that included Merocel patients which is slightly higher than our study.22 Singer et
al. reported a median age of 78 (IQR: 48 to79) for Rapid Rhino which was higher than
the median age in our study.3 The mean age for our entire cohort was 69.03 (95% CI:
65.67 to 72.41) and the median age was 71 (IQR: 61 to 79). Newton et al. reported a
similar median age of 70 for their cohort which included patients treated with Merocel.11
Goljo et al. used a multiple regression equation to evaluate costs on an in-patient basis
and found that their age variable was associated with lower costs -$53 (95% CI: $62 to
$44).10 Our age variable shows a quadratic relationship with total costs, which has so far
not been explored by previous papers. Overall patients under 60, tend to have a negative
association with total costs and patients over 60 have a positive association. Different
models have different thresholds of when the negative association becomes positive. For
the hospital perspective, using the log-gamma model after 53 years old, the patients age
has a positive association with total costs. For the provincial health care perspective, the
threshold was 56 years for log-gamma equation. Like our study, Nithianandan et al.
reported non-significant differences between the sex in terms of totals costs but did report
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a significant difference in total costs for patients who received anticoagulants/antiplatelet
medications which is a contrast to our results.23
Van Wyk et al. reported 15% (7/46) rebleed rates with patients discharged with Merocel,
in contrast to our 39% (23/59).22 However, Van Wky et al. captured rebleeds within 3
days compared to our 2-week period.22 This suggests that use of 3-day window to capture
rebleed events may grossly underestimate the true rebleed rates. Akkan et al. reported a
27% (12/45) rebleed rate for Merocel after 24 hours (this included 3 patients who were
initial failures and were not repacked), which is also lower than our follow-up rebleed
rates (including patients who were not discharged with a pack) of about 39% (24/62).6
Newton et al. had a follow-up rebleed rate for Merocel about 26% (24/92) using the same
two-week time-frame as ours which is slightly lower that our 39% (23/59) rebleed rate
for follow-up rebleeds of patients discharged with nasal packs.11 Singer et al. reported
rebleeds of Rapid Rhino at the patients pack removal visit. A rebleed was defined as the
need to repack after removal of a nasal tampon. The authors of this study reported a 6%
(1/18) rebleed rate (excluding patients who were not discharged with a pack), which
lower than our 19% (3/16) rebleed rate (excluding patients discharged without a nasal
pack).3 This discrepancy could be because they measured rebleed only at their scheduled
follow-up of three days for packing removal and we captured rebleeds until two weeks
without a scheduled follow-up.
Akkan et al. reported a 7% (3/45) initial rebleed rate; these patients required help from an
Otolaryngologist.6 This is similar to our initial rebleed rate of 5% (3/62) in Merocel
patients who required help by an ENT. Other studies calculated “initial failure” of Rapid
Rhino or Merocel, and considered them rebleeds, the closest comparator in our study to
“initial failures” are rebleeds due to ENT consults. Singer et al. reported a 10% (2/20)
rebleed rate initially for Rapid Rhino, which is similar to our 6% (1/17) of patients
initially requiring an ENT conult.3 Their rebleed rate is higher as they define initial
rebleed as a need to repack the nose with another nasal tampon, while our definition is a
need for an ENT consult. Moumoulidis et al. reported an initial failure of management by
Rapid Rhino to be 24% (5/21) and Merocel at 19% (4/21).24 These rates are much higher
than our reported 6% (1/17) for Rapid Rhino and 5% (3/62) for Merocel.24 However, this
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was an RCT where patients received one nasal pack ipsilaterally, and if bleeding was not
controlled, the nasal pack was considered a failure.24 While in our study, an ENT consult
was the closest measurement to an initial failure.
It is difficult to compare our results of cost analysis with other studies as few comparable
cost analyses exists. Nithianandan et al. conducted an economic evaluation in Ottawa for
anterior epistaxis using 30-day total cost where the reported median cost for Merocel
including the first and third quantile.23 This cost included costs for physicians which
would be equivalent to provincial health care perspective costs in our study. They
reported a median cost of $763.98 (IQR: $632.25 to $830.23).23 Our is $406.02 (IQR:
$290.14 to $600.22). Since our follow-up time was two weeks, and costing was up until
the first bleed, our costing seems plausible.
Murray et al. conducted a cost-effectiveness analysis where the median cost for their
Merocel/Vaseline gauze group for the healthcare perspective (including physicians) using
a 30-day time horizon was $2704.51 (IQR: $354.71 to $3846.71).4 This estimate was
much higher than our estimates even when taking into consideration the different followup periods. However, these costs was higher than Nithianandan et al. study who used a
similar timeframe of 30-days. This difference in cost-estimates is mostly likely because
Murray et al. included costs for in-patients as well (surgical/medical ward costs).

3.4.1 Strengths and Limitations
Our study is one of the few studies looking at epistaxis management based in
Canada.4,11,23 It is the only study comparing Rapid Rhino to Merocel directly, that clearly
measures both initial bleeds and has a follow-up period for measuring recurrence events.
Previous studies that directly compared Merocel to Rapid Rhino had either no follow-up
period, only measured management of bleeding initially or at scheduled pack removal or
did not indicate how may patients were packed by Merocel and Rapid Rhino.2,24-28 It is
also the only study currently that has a cost analysis for anterior epistaxis using Merocel
and Rapid Rhino in an outpatient setting. It is one now one of the few studies to take into
consideration both the hospital and the provincial health care perspectives.4
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Our study collected information from medical charts on patients who visited the ERs with
epistaxis in a tertiary academic health sciences centre. Although medical charts are a
good standard for collecting retrospective data, patients reporting to an ER, that tend to
be busy, may not document all relevant information. Therefore, some patients may have
their experience in the ER thoroughly explained while others may have few lines written,
causing variability in the accuracy of the information gathered. Furthermore, patients can
remove their nasal pack at home or visit their family physician for a rebleed, these costs
would not be captured in our study. The major limitation in our study was our small
sample size in the Rapid Rhino group. The small sample size, led to more variability in
the data, making it difficult to conclude on which nasal pack was less costly. Another
limitation in our research was the costing analysis from the provincial health care
perspective. More specifically, ER physicians billing hours were estimated using fees
typically applied in a community setting. Unfortunately gauging hourly fees for an ER
physician is difficult using retrospective data as physicians do not spend the entire time a
patient is in the ER with them, and they often juggle multiple patients at the same time.
Furthermore, to conduct a cost-effectiveness analysis, changes in quality of life for
patients need to be captured. We cannot collect quality of life for patients from 2018 and
currently there is no literature that measures quality of life for either Merocel or Rapid
Rhino. Thus, a formal cost-effectiveness analysis is not possible.
As discussed in the literature review section there are other risk factors and
comorbidities such as smoking status, abuse of drugs and bleeding disorders tend to
increase the occurrence of epistaxis and can confound the relationship between our
treatment and outcome.29-31 These confounders were not adjusted for in our study so there
is potential for model misspecification. We did not stratify between patients who
received warfarin vs. newer anticoagulants such as apixaban and rivaroxaban given
limited sample size. However, there is evidence indicating that warfarin is associated
with a higher rate of bleeds in contrast to apixaban, dabigatran and rivaroxaban which
could affect the results of our study.32 Sowerby et al. noted before that fewer than a third
of ER physicians and residents knew proper first aid methods for managing epistaxis.33 It
is possible that the lack of knowledge and experience in inserting Merocel or Rapid
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Rhino could have lead to more adverse outcomes. Many medical charts gave no
indication of which side a patient’s bleeding occurred, or how many nasal tampons were
utilized. Thus, we did not stratify on these variables but due to this capturing the severity
of a patients bleed became difficult. We use ambulance usage as a proxy for severity and
by excluding ENT consults. However, capturing lateral vs. bilateral bleeds and counting
the number of nasal packs utilized would have been better to capture the severity of a
patients’ bleed.
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3.5 Conclusions
Our study directly compared effectiveness of Merocel to Rapid Rhino by comparing
rebleed rates up to two weeks following discharge with a nasal pack. We also assessed
how total costs were related to patient covariates such as age, sex, medication usage,
ambulance usage and rebleed events. We found an U-shaped relationship between age
and the costs of epistaxis treatment. Our results indicate that our sample failed to provide
evidence that there is a difference between total costs per patient between Merocel and
Rapid Rhino.
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Chapter 4
4 Conclusions and Future Research
4.1 Summary
Management of epistaxis in the emergency room is not an exact science but rather a
combination of guidelines involving patient health circumstances and physician expertise.
Patients often require different interventions in the ER. Sometimes they require no
intervention from physicians, and some other times patients require some help but do not
need a nasal pack inserted into them. Merocel is a popular choice of a nasal pack as they
are less expensive compared to other nasal packs such as Rapid Rhino. Rapid Rhino is
shown to be more comfortable for patients, however. Costs for epistaxis do not only
come from the costs of the nasal pack but also potential returns to the ER for rebleed
events; rebleeds can increase total costs. In Canada, the costs associated with managing
epistaxis burden both the province and the hospital itself. However, there is limited
research on the economic impact on nasal pack choice, especially with rebleeds being
taken into consideration.
We conducted a retrospective study using patient medical charts in two ERs located in
London, Ontario. We measured rebleed rates up until 2 weeks for patients that were
packed by Merocel or Rapid Rhino. Then we assessed costs associated with patient
encounters using propensity score-based weighting for both the hospital and provincial
health care perspectives. Finally, we conducted a sensitivity analysis by excluding (i)
patients that had ENT consultations, (ii) multiple rebleeds within the two-week follow-up
period and (iii) if patients did not return for packing removal.

4.1.1 Literature Review Findings
We conducted a literature review to understand the relationship between Merocel, Rapid
Rhino and other packs in terms of comfort, rebleed rates and economic burden. We found
that Rapid Rhino appeared to be more comfortable compared to other nasal packs.1-4 Data
on health-related quality of life was sparse in the literature making it difficult to conduct
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a cost-effective analysis. Data on rebleed rates was varied.3-14 Often, there were a small
number of individuals included in the studies. Rebleeds were measured at varying ranges,
from the effectiveness of a nasal pack in initially stopping a bleed all the way to 3 months
after the initial visit.3-14 At times, Merocel was compared to interventions such as silver
nitrate and TXA.6,10 These interventions are typically used as a primary management
technique, and if a patient continues to bleed, nasal packing is used. Finally, cost analysis
studies were rare in the literature and existing published studies fail to account for rebleed
costs. For Rapid Rhino and Merocel there is only one study that directly compares costs
for both these nasal pack together, however, this study assessed inpatient costs.14

4.1.2 Study Findings
Our study focused on the costs of considering a change from Merocel to Rapid Rhino in
ERs located in London, Ontario. To provide a thorough analysis, different propensity
score weighting techniques were utilized to ensure patients who received Rapid Rhino
and Merocel are comparable in terms of the observable patient characteristics. Difference
in total costs using Rapid Rhino and Merocel were measured using several different
outcome models including a linear, log-gamma and log-normal. Finally, three separate
sensitivity analysis was conducted by excluding patients that had multiple rebleeds,
excluding patients that required an ENT to manage their bleed and excluding patients
who did not return for packing removal.
When looking at total rebleeds, which include initial failure and any follow-up bleeds,
Merocel has a 42% (26/62) rate of rebleed contrasted to Rapid Rhino 24% (4/17). Rapid
Rhino and Merocel had similar rates of rebleeds requiring help by an ENT during the initial
visit, at about a 6% (1/17) and 5% (3/62) respectively. Merocel had about a 39% (24/62)
follow-up rebleed rate while Rapid Rhino had an 18% (3/17). A log-gamma regression was
the best fit for the hospital perspective. While the provincial health care perspective had
multiple regressions including linear, log-gamma and log-normal. For the hospital
perspective when using the log-gamma regression with CBPS weighting, patients who
received Rapid Rhino, had a non-significant difference in total costs of $61.61 (95% CI: $127.84 to $251.05) per patient, p=0.52. For the province, log-gamma with CBPS
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weighting resulted in Rapid Rhino being associated with a non-significant difference of
$78.14 (95% CI: -$89.54 to $245.83) in costs per patients p=0.36. From these models, our
sample failed to provide evidence that the costs associated with Merocel, or Rapid Rhino
usage is different.

4.2 Future Research
In the future, a prospective trial focused on the hospital’s ER would be beneficial.
According to our results, Rapid Rhino appears to have a lower rate of rebleeds, which led
to lower costs for rebleed visits. However, due to our small Rapid Rhino sample size, we
cannot make any definitive conclusions. A large-scale prospective trial would allow for a
greater number of patients to receive Rapid Rhino and allow us to assess total costs more
precisely. Furthermore, a prospective trial would allow us to measure productivity losses
associated with epistaxis management, and patient quality of life. These data would help
to undertake a cost-effectiveness analysis from a societal perspective as well as hospital
healthcare perspectives.
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Appendix D: Propensity Score results using “pscore” and “teffects” on STATA

Figure D.1: Matching propensity scores after common support restrictions
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Figure D.2. Overlap of propensity scores between Merocel and Rapid Rhino for ATT
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